CEO Ellen K. Donnelly presents Abliva at BioStock Investor Meeting in March 2023
0:19 The patients
1:40 Overview of Abliva
3:13 What are mitochondria?
3:58 Primary mitochondrial diseases
5:34 The time is right for PMD treatment
7:45 Market assessment
9:26 Signs of efficacy
11:08 KL1333 could be on the market by 2026
Abliva discovers and develops medicines for the treatment of mitochondrial diseases.
Subscribe and follow BioStock on:
#BioStock #LifeScience #Abliva
BioStock is Scandinavia’s leading digital news and analysis service with an exclusive focus on the Life Science sector. Our primary editorial office is found at Medicon Village in Lund, one of Sweden’s foremost innovation clusters for life science companies, while our second editorial office is located in central Stockholm with proximity to both life science companies and financial players. We have TV studios on both sites.